Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever

American Journal of Health-System Pharmacy

Volumn 64, Issue 6, 2007, Pages 637-643

  Wingard, John R ^a,b   Leather, Helen L ^c   Wood, Craig A ^d   Gerth, William C ^e   Lupinacci, Robert J ^g   Berger, Marc L ^e   Mansley, Edward C ^f  

^a MMC 366   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d Infectious Diseases

^e Outcomes Research

^f MERCK RESEARCH LABORATORIES   (United States)

^g NONE

Author keywords

Amphotericin B; Antifungals; Caspofungin; Costs; Drug comparisons; Liposomes; Neutropenia; Pharmacoeconomics; Toxicity

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILL; CREATININE BLOOD LEVEL; DRUG COST; DRUG USE; ECONOMIC ASPECT; FEVER; HEALTH CARE COST; HUMAN; KIDNEY FUNCTION; NAUSEA; NEUTROPENIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RASH; SENSITIVITY ANALYSIS; SIDE EFFECT; VOMITING;

EID: 33947608023     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050521     Document Type: Article

References (34)

1. Pizzo PA, Robichaud KJ, Gill FA et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982; 72:101-11.
2. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med. 1989; 86:668-72.
3. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34:730-51.
4. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999; 340:764-71.
5. White MH, Bowden RA, Sandler ES et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998; 27:296-302.
6. Prentice HG, Hann IM, Herbrecht R et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98:711-8.
7. Wingard JR, White MH, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis. 2000; 31:1155-63.
8. Fleming RV, Kantarjian HM, Husni R et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk lymphoma. 2001; 40:511-20.
9. Boogaerts M, Winston DJ, Bow EJ et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 2001; 135:412-22.
10. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002; 346:225-34.
11. Cagnoni PJ, Walsh TJ, Prendergast MM et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol. 2000; 18:2476-83.
12. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004; 351:1391-402.
13. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001; 32:686-93.
14. Harbarth S, Burke JP, Lloyd JF et al. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis. 2002; 35: e120-7.
15. Greenberg RN, Cagnoni PJ, Wingard JR et al. Factors associated with increased hospital costs in patients treated with lipid-based amphotericin B for empirical therapy. J Med Econ. 2002; 5:109-18.
16. National Sales Perspectives. Plymouth Meeting, PA: IMS Health, Inc. 2006 Feb.
17. Wingard JR, Wood CA, Sullivan E et al. Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Clin Ther. 2005; 27:960-9.
18. U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Indexes. www.bls.gov/cpi (accessed 2006 Dec 13).
19. Wilson LS, Reyes CM, Stolpman M et al. The direct cost and incidence of systemic fungal infections. Value Health. 2002; 5:26-34.
20. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998; 27:781-8.
21. Wenzel RP. The Lowbury Lecture. The economics of nosocomial infections. J Hosp Infect. 1995; 31:79-87.
22. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994; 271: 1598-601.
23. Torfs K. Economic aspects of treatment for fungal infections in cancer patients. Eur J Clin Microbiol Infect Dis. 1997; 16:98-107.
24. Goff DA, Sierawski SJ, Fass RJ. Cost analysis of candida infection among surgical intensive care unit patients. Clin Drug Invest. 1996; 12:176-80.
25. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis. 2000; 31:1524-8.
26. Menzin J, Lang KM, Friedman M et al. Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data. Value Health. 2005; 8:140-8.
27. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999; 29:1402-7.
28. Rex JH, Walsh TJ. Estimating the true cost of amphotericin B. Clin Infect Dis. 1999; 29:1408-10.
29. Harbarth S, Samore MH. Reply. (Amphotericin B-related nephrotoxicity has an economic impact on hospitals and health systems.) Clin Infect Dis. 2003; 37:1396-7. Letter.
30. Prendergrast MM, Tong KB. Reply. (Amphotericin B-related nephrotoxicity has an economic impact on hospitals and health systems.) Clin Infect Dis. 2003; 37:1396. Letter.
31. Bates DW, Su L, Yu DT et al. Correlates of acute renal failure in patients receiving patenterai amphotericin B. Kidney Int. 2001; 60:1452-9.
32. Wenzel R, Del Favero A, Kibbler C et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother. 2005; 55:352-61.
33. Lewis JS, Boucher HW, Lubowski T et al. Economic advantage of voriconazole (VRC) for primary treatment of invasive aspergillosis compared to conventional amphotericin B (CAB). Presented at ICAAC Conference. Chicago, IL; 2003. Abstract.
34. Roden MM, Nelson LD, Knudsen TA et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin Infect Dis. 2003; 36:1213-20.